| # | Title | Journal | Year | Citations |
|---|
| 1 | Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 | Cardiovascular Diabetology | 2018 | 1,198 |
| 2 | Association between insulin resistance and the development of cardiovascular disease | Cardiovascular Diabetology | 2018 | 1,031 |
| 3 | Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice | Cardiovascular Diabetology | 2005 | 719 |
| 4 | Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease | Cardiovascular Diabetology | 2006 | 564 |
| 5 | Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies | Cardiovascular Diabetology | 2018 | 388 |
| 6 | The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus | Cardiovascular Diabetology | 2014 | 381 |
| 7 | Endothelial dysfunction: a comprehensive appraisal | Cardiovascular Diabetology | 2006 | 363 |
| 8 | Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance | Cardiovascular Diabetology | 2014 | 359 |
| 9 | SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart | Cardiovascular Diabetology | 2019 | 359 |
| 10 | Diabetes, cardiovascular disease and the microcirculation | Cardiovascular Diabetology | 2018 | 320 |
| 11 | Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes | Cardiovascular Diabetology | 2017 | 303 |
| 12 | Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice | Cardiovascular Diabetology | 2014 | 296 |
| 13 | On the use of a continuous metabolic syndrome score in pediatric research | Cardiovascular Diabetology | 2008 | 274 |
| 14 | Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study | Cardiovascular Diabetology | 2017 | 274 |
| 15 | Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin | Cardiovascular Diabetology | 2021 | 271 |
| 16 | The effect of dapagliflozin treatment on epicardial adipose tissue volume | Cardiovascular Diabetology | 2018 | 252 |
| 17 | Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus | Cardiovascular Diabetology | 2013 | 215 |
| 18 | Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes | Cardiovascular Diabetology | 2011 | 210 |
| 19 | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons | Cardiovascular Diabetology | 2005 | 209 |
| 20 | Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study | Cardiovascular Diabetology | 2009 | 208 |
| 21 | Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes | Cardiovascular Diabetology | 2016 | 207 |
| 22 | Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes | Cardiovascular Diabetology | 2015 | 206 |
| 23 | Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis | Cardiovascular Diabetology | 2019 | 206 |
| 24 | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes | Cardiovascular Diabetology | 2017 | 205 |
| 25 | Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme | Cardiovascular Diabetology | 2012 | 203 |
| 26 | Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties | Cardiovascular Diabetology | 2011 | 198 |
| 27 | Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) | Cardiovascular Diabetology | 2014 | 198 |
| 28 | Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study | Cardiovascular Diabetology | 2016 | 190 |
| 29 | Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? | Cardiovascular Diabetology | 2014 | 182 |
| 30 | SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice | Cardiovascular Diabetology | 2018 | 178 |
| 31 | Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study | Cardiovascular Diabetology | 2017 | 177 |
| 32 | Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate | Cardiovascular Diabetology | 2005 | 176 |
| 33 | Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? | Cardiovascular Diabetology | 2008 | 172 |
| 34 | YKL-40 - an emerging biomarker in cardiovascular disease and diabetes | Cardiovascular Diabetology | 2009 | 171 |
| 35 | Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats | Cardiovascular Diabetology | 2019 | 170 |
| 36 | Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products | Cardiovascular Diabetology | 2006 | 169 |
| 37 | Protein kinase RNA- like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)- mediated endoplasmic reticulum stress- induced apoptosis in diabetic cardiomyopathy | Cardiovascular Diabetology | 2013 | 169 |
| 38 | Association between triglyceride glucose index and arterial stiffness in Korean adults | Cardiovascular Diabetology | 2018 | 169 |
| 39 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study | Cardiovascular Diabetology | 2014 | 168 |
| 40 | Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies | Cardiovascular Diabetology | 2014 | 167 |
| 41 | Diagnostic approaches for diabetic cardiomyopathy | Cardiovascular Diabetology | 2017 | 165 |
| 42 | Influence of diabetes mellitus on heart failure risk and outcome | Cardiovascular Diabetology | 2003 | 163 |
| 43 | Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: The Rural Chinese Cohort Study | Cardiovascular Diabetology | 2017 | 163 |
| 44 | Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome | Cardiovascular Diabetology | 2005 | 162 |
| 45 | Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations | Cardiovascular Diabetology | 2022 | 162 |
| 46 | Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome | Cardiovascular Diabetology | 2020 | 161 |
| 47 | Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study | Cardiovascular Diabetology | 2019 | 158 |
| 48 | Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state | Cardiovascular Diabetology | 2006 | 157 |
| 49 | Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes | Cardiovascular Diabetology | 2018 | 157 |
| 50 | Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study | Cardiovascular Diabetology | 2013 | 152 |
